Radiation mitigation of the intestinal acute radiation injury in mice by 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine

Author:

Duhachek-Muggy Sara1,Bhat Kruttika1,Medina Paul1,Cheng Fei1,He Ling1,Alli Claudia1,Saki Mohammad1,Muthukrishnan Sree Deepthi2,Ruffenach Gregoire3,Eghbali Mansoureh3,Vlashi Erina14,Pajonk Frank14

Affiliation:

1. Department of Radiation Oncology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, California

2. Department of Psychiatry Semel Institute of Neuroscience and Human Behavior, UCLA, Los Angeles, California

3. Department of Anesthesiology, Division of Molecular Medicine, Cardiovascular Research Laboratory, David Geffen School of Medicine University of California Los Angeles, Los Angeles, California

4. Jonsson Comprehensive Cancer Center University of California Los Angeles, Los Angeles, California

Abstract

Abstract The objective of the study was to identify the mechanism of action for a radiation mitigator of the gastrointestinal (GI) acute radiation syndrome (ARS), identified in an unbiased high-throughput screen. We used mice irradiated with a lethal dose of radiation and treated with daily injections of the radiation mitigator 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine to study its effects on key pathways involved in intestinal stem cell (ISC) maintenance. RNASeq, quantitative reverse transcriptase-polymerase chain reaction, and immunohistochemistry were performed to identify pathways engaged after drug treatment. Target validation was performed with competition assays, reporter cells, and in silico docking. 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine activates Hedgehog signaling by binding to the transmembrane domain of Smoothened, thereby expanding the ISC pool, increasing the number of regenerating crypts and preventing the GI-ARS. We conclude that Smoothened is a target for radiation mitigation in the small intestine that could be explored for use in radiation accidents as well as to mitigate normal tissue toxicity during and after radiotherapy of the abdomen. Significance statement Exposure to lethal doses of ionizing radiation manifests in a symptom complex that is summarized as acute radiation syndrome (ARS) and the extent of radiation damage to the hematopoietic and gastrointestinal (GI) systems codetermine the acute survival of the exposed individual. So far, no person who experienced a full-scale GI-ARS has ever survived. This creates a—so far—mostly unmet need to develop countermeasures that mitigate the effects of lethal radiation doses when given after radiation exposure. This study presents that a piperazine compound prevents GI-ARS in mice when given 24 hours after a lethal dose of radiation and uncovers the underlying mechanism of action, thus providing a basis for a future rational development of effective radiation mitigators.

Funder

National Cancer Institute

National Institute of Allergy and Infectious Diseases

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3